| Radioactive contamination and transfer | Lifetime | 14 | US 10 | 99.56 |
| Radioactive element chemistry and processing | Lifetime | 57 | US 27 | 99.45 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 38 | US 18 | 99.30 |
| Schizophrenia research and treatment | Lifetime | 54 | US 29 | 99.73 |
| Psychiatric care and mental health services | Lifetime | 21 | US 11 | 99.49 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 99 | US 59 | 99.16 |
| Radiation Dose and Imaging | Lifetime | 108 | US 57 | 99.05 |
| Treatment of Major Depression | Lifetime | 73 | US 36 | 99.32 |
| Intraocular Surgery and Lenses | Lifetime | 127 | US 69 | 99.12 |
| Mental Health and Psychiatry | Lifetime | 91 | US 38 | 99.09 |
| Bipolar Disorder and Treatment | Lifetime | 120 | US 68 | 99.15 |
| Electroconvulsive Therapy Studies | Lifetime | 51 | US 28 | 99.02 |
| Prion Diseases and Protein Misfolding | Lifetime | 62 | US 32 | 98.76 |
| Nuclear and radioactivity studies | Lifetime | 262 | US 60 | 97.44 |
| Pharmaceutical studies and practices | Lifetime | 274 | US 134 | 97.68 |
| Trace Elements in Health | Lifetime | 371 | US 155 | 97.67 |
| Radioactivity and Radon Measurements | Lifetime | 253 | US 56 | 97.20 |
| Blood disorders and treatments | Lifetime | 202 | US 83 | 97.44 |
| Ocular Disorders and Treatments | Lifetime | 67 | US 30 | 96.51 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 303 | US 138 | 97.10 |
| Medical Imaging and Pathology Studies | Lifetime | 673 | US 308 | 96.80 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 80 | US 27 | 95.56 |
| Lanthanide and Transition Metal Complexes | Lifetime | 986 | US 222 | 95.86 |
| Neurological diseases and metabolism | Lifetime | 319 | US 118 | 96.14 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 978 | US 364 | 96.07 |
| Graphite, nuclear technology, radiation studies | Lifetime | 705 | US 180 | 94.76 |
| Ophthalmology and Visual Impairment Studies | Lifetime | 559 | US 220 | 96.33 |
| Connexins and lens biology | Lifetime | 465 | US 213 | 94.81 |
| Chemical Reactions and Isotopes | Lifetime | 571 | US 286 | 94.75 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 114 | US 47 | 94.51 |
| Traumatic Ocular and Foreign Body Injuries | Lifetime | 410 | US 231 | 93.64 |
| Restraint-Related Deaths | Lifetime | 268 | US 111 | 92.37 |
| Healthcare Decision-Making and Restraints | Lifetime | 510 | US 205 | 92.11 |
| Child Abuse and Related Trauma | Lifetime | 182 | US 107 | 88.67 |
| Ophthalmology and Visual Health Research | Lifetime | 502 | US 151 | 82.77 |
| Whipple's Disease and Interleukins | Lifetime | 970 | US 260 | 49.10 |
| Schizophrenia research and treatment | 2021-2025 | 25 | US 5 | 99.20 |
| Blood disorders and treatments | 2021-2025 | 10 | US 2 | 97.80 |
| Tryptophan and brain disorders | 2021-2025 | 163 | US 41 | 96.13 |
| Treatment of Major Depression | 2021-2025 | 61 | US 22 | 96.76 |
| Mental Health and Psychiatry | 2021-2025 | 69 | US 16 | 94.82 |
| Bipolar Disorder and Treatment | 2021-2025 | 299 | US 56 | 91.99 |
| Neurotransmitter Receptor Influence on Behavior | 2021-2025 | 625 | US 307 | 79.78 |
| Psychiatric care and mental health services | 2021-2025 | 227 | US 17 | 76.47 |
| Electroconvulsive Therapy Studies | 2021-2025 | 652 | US 167 | 61.19 |
